Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 770371 plus pembrolizumab with or without cetuximab vs pembrolizumab in first-line metastatic or recurrent HNSCC
jRCT2011240074Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Pembrolizumab monotherapy, BI 770371 plus pembrolizumab and BI 770371 plus pembrolizumab plus cetuximab (3 arms). Primary endpoint: Objective response with confirmation. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2011240074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240074.